ArticleHaematologica2026

Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study.

Gang An et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.